<DOC>
	<DOCNO>NCT01183858</DOCNO>
	<brief_summary>This prospective , double-blind , randomize study evaluate safety efficacy two dose level erlotinib [ Tarceva ] progression-free survival , response disease control rate overall survival patient advance metastatic non-small cell lung cancer ( NSCLC ) failure first-line platinum-based chemotherapy . Patients must current smoker intend stop smoking study . Patients randomize receive either 150 mg 300 mg study drug single daily oral dos . Treatment continue disease progression .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Compare Two Different Doses Currently Smoking Patients With Advanced Metastatic Non-Small Cell Lung Cancer ( CURRENTS )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient age ≥18 year inoperable , locally advanced ( stage IIIB/IV ) supraclavicular lymph node metastases malignant pleural pericardial effusion ) metastatic ( stage IV ) nonsmall cell lung cancer ( NSCLC ) Disease must characterize accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Patients receive one prior platinumbased chemotherapy regimen advance NSCLC , must recover treatmentrelated toxicity Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy ≥12 week Current cigarette smoker ( smoke &gt; 100 cigarette entire lifetime currently smoke average ≥1 cigarette per day ) , intend stop study Prior antibody small molecule therapy Epidermal growth factor receptor ( EGFR ) Radiotherapy within 28 day prior enrollment Received one line chemotherapy locally advanced/metastatic NSCLC ( firstline maintenance chemotherapy firstline platinumbased chemotherapy allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>